IPSEN |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121.4 EUR | +0.33% |
|
+1.51% | +12.51% |
| May. 14 | Ipsen: share price up, analyst raises target | CF |
| May. 14 | IPSEN : Barclays raises its target price | CF |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 3.46B 3.76B | Sales 2025 * | 3.7B 4.02B | Capitalization | 10.03B 10.88B |
|---|---|---|---|---|---|
| Net income 2024 * | 645M 700M | Net income 2025 * | 718M 779M | EV / Sales 2024 * | 2.74 x |
| Net cash position 2024 * | 563M 611M | Net cash position 2025 * | 1.18B 1.29B | EV / Sales 2025 * | 2.39 x |
| P/E ratio 2024 * |
15.6
x | P/E ratio 2025 * |
14.1
x | Employees | 5,325 |
| Yield 2024 * |
0.99% | Yield 2025 * |
1% | Free-Float | 41.52% |
More Fundamentals
* Assessed data
More news
Latest transcript on Ipsen
More press releases
More news
| 1 day | +0.33% | ||
| 1 week | +1.51% | ||
| Current month | +6.40% | ||
| 1 month | +12.83% | ||
| 3 months | +15.73% | ||
| 6 months | +15.18% | ||
| Current year | +12.51% |
1 week
118.40
122.60
1 month
105.30122.60
Current year
99.70122.60
1 year
99.70130.70
3 years
77.00130.70
5 years
34.20130.70
10 years
31.50155.95
| Managers | Title | Age | Since |
|---|---|---|---|
David Loew
CEO | Chief Executive Officer | 57 | 20-06-30 |
| Director of Finance/CFO | 55 | 14-11-02 | |
| Chairman | 66 | 10-11-21 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Margaret Liu
BRD | Director/Board Member | 66 | 17-06-06 |
Karen Witts
BRD | Director/Board Member | 61 | 22-01-20 |
Michèle Ollier
BRD | Director/Board Member | 65 | 15-05-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.83% | 2 M€ | +11.90% | ||
| 0.43% | 242 M€ | +9.80% | ||
| 0.31% | 3 M€ | +9.95% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-16 | 121.4 | +0.33% | 40,831 |
| 24-05-15 | 121 | -0.33% | 71,196 |
| 24-05-14 | 121.4 | +2.02% | 81,582 |
| 24-05-13 | 119 | -0.75% | 37,988 |
| 24-05-10 | 119.9 | +0.25% | 58,741 |
Real-time Euronext Paris, May 16, 2024 at 11:35 am EDT
More quotes
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows:
- oncology (75.2%);
- neuroscience (21.1%);
- rare diseases (3.7%).
At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide.
Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
Sector
Pharmaceuticals
Calendar
2024-05-28
- Annual General Meeting
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
16
Last Close Price
121.4
EUR
Average target price
126.3
EUR
Spread / Average Target
+4.07%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +12.51% | 10.86B | |
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
- Stock Market
- Equities
- IPN Stock
